HIV drug combo found to have no benefit for hospitalised Covid-19 patients in UK trial3Photo© hindustantimes.com

HIV drug combo found to have no benefit for hospitalised Covid-19 patients in UK trial

, 6 news, 3 views

A combination of antiviral drugs commonly used to treat HIV showed no beneficial effects in patients hospitalised with COVID-19 in a large-scale randomised trial, scientists in the UK have found.

The findings “convincingly rule out any meaningful mortality benefit of lopinavir-ritonavir in the hospitalised COVID-19 patients we studied,” the scientists running the RECOVERY trial at the University of Oxford said in a statement on Monday.

In March, the RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including lopinavir-ritonavir, an antiviral treatment commonly used to treat HIV.